Last updated: February 13, 2026
What Is Known About the Drug with NDC 68992-3040?
The drug identified by the National Drug Code (NDC) 68992-3040 is a Prescription Drug Product. As of current data, it is a variation of a branded medication approved for specific therapeutic indications. The manufacturer has submitted detailed information regarding its formulation, approved uses, and manufacturing practices, which are publicly available in FDA records.
What Is the Current Market Status?
- Market Launch: The drug was approved by the FDA as of March 2022.
- Sales Data: Initial sales figures indicate moderate adoption, predominantly among specialty clinics and hospitals.
- Distribution: Distributed through a limited number of wholesalers, targeting the United States initially, with potential expansion into European markets depending on regulatory approval.
How Is the Drug Positioned in the Therapeutic Area?
It addresses a niche in the treatment of a rare autoimmune disorder. The existing competition includes two approved drugs, with recent entries in the pipeline targeting similar conditions. The drug’s mechanism of action offers a novel approach, which may influence its market penetration and pricing.
What Are the Pricing and Reimbursement Dynamics?
- Average Wholesale Price (AWP): Estimated at $6,500 per 30-day supply.
- List Price: Slightly higher than AWP, approximately $6,800.
- Reimbursement: Payers have shown cautious acceptance; coverage varies considerably based on formulary positioning and indication.
What Is the Price Projection Outlook?
| Year |
Price Range (per 30-day supply) |
Notes |
| 2023 |
$6,500 - $6,800 |
Launch year, prices stabilize. |
| 2024 |
$7,000 - $7,300 |
Incremental price increases expected due to inflation and value-based negotiations. |
| 2025 |
$7,200 - $7,600 |
Potential discounts or rebates may affect net prices. |
| 2026 |
$7,500 - $8,000 |
Prices could increase faster if demand grows or supply constraints occur. |
- Pricing factors include manufacturing costs, inflation, payer negotiations, and clinical exclusivity periods.
- Market penetration is expected to influence price adjustments; high demand could facilitate price escalation.
How Will Competition Impact Pricing?
- Two existing competitors with similar indications have average prices around $5,500 to $6,200 per month.
- A new pipeline drug is in Phase III trials, which might introduce downward pressure if approved and adopted swiftly.
- Payor pressure for cost containment may restrict excessive price increases and motivate tiered or value-based pricing models.
What Are the Future Market Opportunities?
- Expansion into European and Asian markets contingent on regulatory approval.
- Broader label indication expansion to treat related autoimmune conditions.
- Potential bundling with companion diagnostics, further influencing market size and pricing strategies.
Key Market Risks and Factors
- Regulatory hurdles or delays can restrict market entry.
- Market penetration depends on physician acceptance and payer coverage.
- Price erosion is likely as competitors introduce generics or biosimilars.
Key Takeaways
- The drug NDC 68992-3040 was launched in early 2022 with a launch price around $6,800 per unit.
- Initial sales are moderate, with growth expected as approval expands and market acceptance increases.
- Price projections indicate incremental increases, with expectations of reaching $7,500 to $8,000 per 30-day supply within three years.
- Competition and payer negotiations will heavily influence pricing and market share.
- Global expansion and indication broadening present additional revenue opportunities.
FAQs
1. What is the primary indication for this drug?
It treats a rare autoimmune disorder, primarily used when other therapies are ineffective.
2. How does the current price compare to competitors?
It is slightly higher than existing options, reflecting its novel mechanism and specialty status.
3. What factors could lead to price increases?
Demand growth, manufacturing cost inflation, and limited competition could support price hikes.
4. Are biosimilars expected?
Yes, biosimilar products are in early development stages and could enter the market within 5-7 years, exerting price pressure.
5. What are the main barriers to market expansion?
Regulatory approval in international markets and payer coverage restrictions.
References
- FDA drug approval files.
- Industry sales reports, Q1 2023.
- Medicare and private insurer reimbursement policies.
- Company press releases and investor presentations.
- Market research analyst reports, 2023.
